Skip to main content

Table 4 Adjusted estimated marginal mean EORTC QLQ-C15-PAL post-treatment scores

From: Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide

Scales
Mean (95% CI)
Octreotide (N = 52) Placebo (N = 54) Mean difference (95% CI) P-value
Overall HrQoLa 35.31 (21.68, 48.94) 34.86 (21.30, 48.41) 0.45 (−10.35, 11.26) 0.935
Physical functioninga 33.97 (21.30, 46.64) 31.01 (20.31, 41.69) 2.97 (−6.52, 12.46) 0.539
Emotional functioninga 60.30 (45.18, 75.42) 58.95 (46.22, 71.67) 1.36 (−10.40, 13.12) 0.821
Fatigueb 73.58 (60.28, 86.87) 72.88 (59.75, 86.00) 0.70 (−10.07, 11.46) 0.899
Nausea & vomitingb 51.45 (33.98, 68.91) 47.79 (32.39, 63.18) 3.66 (−10.35, 17.68) 0.608
Painb 56.38 (40.27, 72.49) 55.53 (42.61, 68.44) 0.85 (− 11.08, 12.79) 0.888
Dyspnoeab 31.67 (17.77, 45.54) 29.76 (17.00, 42.53) 1.89 (−9.69, 13.48) 0.748
Insomniab 41.00 (26.17, 55.84) 48.14 (34.14, 62.14) − 7.14 (− 20.88, 6.61) 0.308
Appetite lossb 52.10 (34.34, 69.87) 52.09 (34.90, 69.28) 0.16 (−14.23, 14.26) 0.998
Constipationb 49.45 (32.91, 65.99) 51.47 (37.22, 65.72) −2.02 (−16.22, 12.19) 0.780
  1. HrQoL Health related quality of life
  2. ahigher scores represent better outcomes
  3. bhigher scores represent greater symptom burden